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A population-based analysis of patterns of care and outcome in glioma pa-
tients diagnosed 1980-1994 in the Canton of Zurich, Switzerland, has con-
firmed the overall poor prognosis of glioblastoma. To explore changes in
outcome over the last decades, the registry datawere re-evaluated for patients
diagnosed in the time frame2005-2009. Patients diagnosedwith glioblastoma
in the Canton of Zurich from 2005-2009 were identified by the Cancer
Registry Zurich. Clinical and epidemiological data, as well as molecular
markers were assessed, and analyzed using the Kaplan-Meier method and
the Cox proportional hazards model. In the current database, there were
264 patients with glioblastoma, including 256 primary glioblastomas with
an annual incidence of 3.98 compared to 3.55 in the former patient group.
Median age at diagnosis was 60.0 years recently as opposed to 61.3 years pre-
viously. Overall survival (OS) for all glioblastoma patients was 41.7% at 1
year, 22.7% at 2 years and 13.1% at 3 years in the present study while previ-
ously theOSwas significantly lower, namely 17.7% at 1 year, 3.3%at 2 years
and 1.2% at 3 years, respectively. Median OS for primary glioblastomas was
11.0months for the period ending 2009 versus 4.7months for the patient pop-
ulation of 1980-1994. In the present study, by treatment, the median OS for
best supportive care, radiotherapyalone, temozolomide aloneor radiotherapy
plus temozolomide was 2.0, 6.0, 6.0 or 17.0 months, respectively.
Multivariate analysis revealed age, KPS, extent of resection, adjuvant treat-
ment regimens, yearofdiagnosis, IDH-1mutation status andMGMTpromot-
ermethylation status significantly associatedwith survival. TheOSof patients
in the Canton of Zurich with newly diagnosed glioblastoma hasmarkedly im-
proved from the period of 1980-1994 to 2005-2009.
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